Citius Oncology Inc CTOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Trading Information
- Previous Close Price
- $0.57
- Day Range
- $0.53–0.58
- 52-Week Range
- $0.49–1.83
- Bid/Ask
- $0.53 / $0.55
- Shares Outstanding
- 105.76M
- Market Cap
- $56.58M
- Volume/Avg
- 83,079 / 115,780
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 0
- Website
- https://www.citiusonc.com
Valuation
Metric | CTOR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.50 |
Price/Sales | 7.54 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CTOR |
|---|---|
Quick Ratio | 0.29 |
Current Ratio | 0.73 |
Interest Coverage | −83.18 |
Quick Ratio
CTOR
Profitability
Metric | CTOR |
|---|---|
Return on Assets (Normalized) | −34.46% |
Return on Equity (Normalized) | −84.05% |
Return on Invested Capital (Normalized) | −74.46% |
Return on Assets
CTOR
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|^vP&gjnr | LOCK|T!qg | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|^!RvRF# | LOCK|^#^s | $51B | |||
| Haleon PLC ADR HLN | LOCK|Zsq$!n@ | LOCK|<!@ | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|#<?@>x? | LOCK|q> | $34B | |||
| Viatris Inc VTRS | LOCK|MH$Bm? | LOCK|d& | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|c< | LOCK|RcW | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|Kfq$xZB | LOCK|pZX | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|KJST!q | LOCK|D# | $5B | |||
| Perrigo Co PLC PRGO | LOCK|NX%Cl% | LOCK|zM | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|YZ$fzQB | LOCK|sVs&M | $2B |